HRP20160334T1 - Pirano [3, 2 - d][1, 3]tiazol kao inhibitori glikozidaze - Google Patents

Pirano [3, 2 - d][1, 3]tiazol kao inhibitori glikozidaze Download PDF

Info

Publication number
HRP20160334T1
HRP20160334T1 HRP20160334TT HRP20160334T HRP20160334T1 HR P20160334 T1 HRP20160334 T1 HR P20160334T1 HR P20160334T T HRP20160334T T HR P20160334TT HR P20160334 T HRP20160334 T HR P20160334T HR P20160334 T1 HRP20160334 T1 HR P20160334T1
Authority
HR
Croatia
Prior art keywords
image
denotes
atoms
compound
disease
Prior art date
Application number
HRP20160334TT
Other languages
English (en)
Croatian (hr)
Inventor
Marianne DONNELLY
Hui QIU
Henry Yu
Lesley Liu-Bujalski
Andreas Goutopoulos
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20160334T1 publication Critical patent/HRP20160334T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20160334TT 2011-08-25 2012-08-22 Pirano [3, 2 - d][1, 3]tiazol kao inhibitori glikozidaze HRP20160334T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527323P 2011-08-25 2011-08-25
EP12753341.2A EP2748171B1 (en) 2011-08-25 2012-08-22 Pyrano [3, 2 - d][1, 3]thiazole as glycosidase inhibitors
PCT/US2012/051785 WO2013028715A1 (en) 2011-08-25 2012-08-22 Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors

Publications (1)

Publication Number Publication Date
HRP20160334T1 true HRP20160334T1 (hr) 2016-05-06

Family

ID=46759099

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160334TT HRP20160334T1 (hr) 2011-08-25 2012-08-22 Pirano [3, 2 - d][1, 3]tiazol kao inhibitori glikozidaze

Country Status (21)

Country Link
US (2) US8884023B2 (enExample)
EP (1) EP2748171B1 (enExample)
JP (1) JP5893738B2 (enExample)
KR (1) KR102008032B1 (enExample)
CN (1) CN103930428B (enExample)
AU (1) AU2012298949B2 (enExample)
BR (1) BR112014004219B1 (enExample)
CA (1) CA2845149C (enExample)
DK (1) DK2748171T3 (enExample)
EA (1) EA022562B1 (enExample)
ES (1) ES2568603T3 (enExample)
HR (1) HRP20160334T1 (enExample)
HU (1) HUE029390T2 (enExample)
IL (1) IL231008A (enExample)
MX (1) MX358463B (enExample)
PL (1) PL2748171T3 (enExample)
RS (1) RS54773B1 (enExample)
SG (1) SG2014009617A (enExample)
SI (1) SI2748171T1 (enExample)
WO (1) WO2013028715A1 (enExample)
ZA (1) ZA201400387B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201249848A (en) 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
BR112013016179A2 (pt) 2010-12-23 2018-07-10 Alectos Therapeutics Inc inibidores seletivos da glicosidase e usos dos mesmos.
WO2012126091A1 (en) 2011-03-24 2012-09-27 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9718854B2 (en) * 2011-03-31 2017-08-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
MX364602B (es) 2011-06-27 2019-05-02 Alectos Therapeutics Inc Inhibidores selectivos de glicosidasa y usos de los mismos.
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US8884023B2 (en) * 2011-08-25 2014-11-11 Merck Patent Gmbh Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2890676B1 (en) 2012-08-31 2018-12-05 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2914604A4 (en) 2012-10-31 2016-07-20 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
WO2014100934A1 (en) * 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
MX381417B (es) 2014-08-28 2025-03-12 Asceneuron Sa Inhibidores de glucosidasa.
US10571963B2 (en) * 2015-09-18 2020-02-25 Toray Industries, Inc. Housing
JP6971999B2 (ja) 2016-02-25 2021-11-24 エースニューロン・ソシエテ・アノニム ピペラジン誘導体の酸付加塩
CN108884077A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
JP2019506430A (ja) 2016-02-25 2019-03-07 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
CA3110032A1 (en) 2018-08-22 2020-02-27 Asceneuron S.A. Succinate and fumarate acid addition salts of piperazine derivatives
TW202130643A (zh) * 2019-10-29 2021-08-16 美商百健Ma公司 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006220187B2 (en) * 2005-03-01 2012-11-08 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
AU2007210002A1 (en) * 2006-01-30 2007-08-09 Irm Llc Compounds and compositions as PPAR modulators
CN101595111A (zh) * 2006-08-31 2009-12-02 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
EP2057171A4 (en) * 2006-08-31 2010-04-21 Univ Fraser Simon SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012061927A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
BR112013016179A2 (pt) 2010-12-23 2018-07-10 Alectos Therapeutics Inc inibidores seletivos da glicosidase e usos dos mesmos.
US8884023B2 (en) * 2011-08-25 2014-11-11 Merck Patent Gmbh Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors

Also Published As

Publication number Publication date
SG2014009617A (en) 2014-05-29
CN103930428A (zh) 2014-07-16
US20150018318A1 (en) 2015-01-15
KR102008032B1 (ko) 2019-08-06
HK1196607A1 (zh) 2014-12-19
US20140243370A1 (en) 2014-08-28
IL231008A (en) 2016-04-21
BR112014004219B1 (pt) 2021-11-30
RS54773B1 (sr) 2016-10-31
ES2568603T3 (es) 2016-05-03
BR112014004219A2 (pt) 2017-03-14
EP2748171B1 (en) 2016-02-03
CA2845149A1 (en) 2013-02-28
DK2748171T3 (en) 2016-05-09
ZA201400387B (en) 2015-05-27
MX2014002031A (es) 2014-03-21
EA201490493A1 (ru) 2014-06-30
EA022562B1 (ru) 2016-01-29
IL231008A0 (en) 2014-03-31
CN103930428B (zh) 2016-05-11
EP2748171A1 (en) 2014-07-02
HUE029390T2 (en) 2017-02-28
AU2012298949B2 (en) 2016-09-22
WO2013028715A1 (en) 2013-02-28
JP5893738B2 (ja) 2016-03-23
AU2012298949A1 (en) 2014-01-30
SI2748171T1 (sl) 2016-06-30
US8884023B2 (en) 2014-11-11
KR20140054007A (ko) 2014-05-08
CA2845149C (en) 2019-12-31
MX358463B (es) 2018-08-22
US9469657B2 (en) 2016-10-18
JP2014527060A (ja) 2014-10-09
PL2748171T3 (pl) 2016-06-30

Similar Documents

Publication Publication Date Title
HRP20190857T1 (hr) Inhibitori glikozidaze
ES2568603T3 (es) Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasas
JP2014527060A5 (enExample)
JP6106603B2 (ja) ヘテロアリール化合物及びその使用方法
ME02390B (me) Inhibitori beta sekretaze
US20120135997A1 (en) Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
FI3487505T3 (fi) Diaminofenotiatsiinien antaminen ja annostus
JP2019510006A5 (enExample)
US10676470B2 (en) Inhibitors of lysine gingipain
WO2013022047A1 (ja) シクロプロパンアミン化合物
JPWO2016148114A1 (ja) 酸化ストレス誘導神経細胞死抑制化合物
IN2014MN01756A (enExample)
HRP20120876T1 (hr) Brzo disocirajuä†i antagonisti dopamin 2 receptora
IL259674A (en) Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases
RS61890B1 (sr) Derivati hromana, izohromana i dihidroizobenzofurana kao mglur2-negativni alosterni modulatori, kompozicije i njihova upotreba
JP2024526138A (ja) 新規な化合物及びその使用
JP6302480B2 (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
WO2012031383A1 (zh) 酰胺类化合物
JP2017521489A (ja) ピリミジン化合物およびその使用方法
HRP20130869T1 (hr) 5-(3,4-dikloro-fenil)-n-(2-hidroksi-cikloheksil)-6-(2,2,2-trifluoro-etoksi)-nikotinamid i njegove soli kao sredstva za poveä†anje hdl-kolesterola
NZ590315A (en) Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
EP4048399A1 (en) Inhibitors of trek (twik related k+ channels) channel function
HRP20230318T1 (hr) Derivat pirimidin sulfamida, postupak pripreme i njegova medicinska primjena
JPWO2008016002A1 (ja) プロトンポンプ阻害剤を含有するアミロイドβ産生抑制剤
UA116480C2 (uk) Похідна біфенілу та спосіб її одержання